Can an Oral Peptide Transform Ulcerative Colitis Care?
Managing moderate to severe inflammatory bowel disease remains challenging for clinicians. Currently, biologic treatments targeting interleukin-23 require intravenous or subcutaneous administration. However, evaluating oral icotrokinra for ulcerative colitis offers an exciting new therapeutic avenue. This novel oral peptide selectively blocks interleukin-23 receptor signaling directly within the gut mucosa.
Evaluating Icotrokinra for Ulcerative Colitis in ANTHEM-UC
The phase 2b ANTHEM-UC trial evaluated the efficacy and safety of once-daily oral icotrokinra. Specifically, investigators enrolled 252 adult patients with moderately to severely active ulcerative colitis. In fact, investigators randomly assigned participants to receive 100 mg, 200 mg, or 400 mg of icotrokinra, or placebo. Furthermore, the trial included patients who previously failed conventional or advanced biologic therapies. Consequently, the study reflected a clinically challenging real-world patient cohort.
Key Clinical and Endoscopic Trial Outcomes
All three active treatment groups achieved remarkable therapeutic success at week 12. For instance, the 400-mg dose group achieved a 63% clinical response rate. Similarly, the 200-mg and 100-mg cohorts achieved 58% and 55% response rates, respectively. In contrast, only 27% of placebo-treated patients showed a clinical response. Moreover, patients receiving icotrokinra experienced notable rates of clinical remission and mucosal healing. In addition, endoscopic improvements occurred rapidly without causing unexpected adverse events.
Clinical Implications for Gastroenterology Practice
Injectable biologics often present administration hurdles, cold-chain storage demands, and needle hesitation. Therefore, a potent once-daily oral peptide provides substantial clinical utility. Clinicians can achieve targeted interleukin-23 pathway blockade without parenteral injections. Additionally, the targeted peptide acts locally while maintaining a clean systemic safety profile. Thus, future phase 3 confirmation could transform contemporary ulcerative colitis practice worldwide.
Frequently Asked Questions
Q1: How does icotrokinra differ from existing IL-23 biologic agents?
Unlike monoclonal antibodies that require parenteral injections, icotrokinra is a first-in-class oral peptide. Consequently, it selectively blocks the interleukin-23 receptor via once-daily oral tablets.
Q2: What primary endpoint did the phase 2b trial assess at week 12?
The primary endpoint was clinical response at week 12 based on the modified Mayo score. Importantly, all three icotrokinra doses showed significant superiority over placebo.
Q3: Were there any unexpected safety signals reported in the study?
No unexpected safety signals emerged during the 12-week trial period. Furthermore, adverse event rates remained balanced between the active icotrokinra groups and placebo.
References
- Abreu MT et al. Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis. N Engl J Med. 2026 Oct 15. doi: 10.1056/NEJMoa2604435. PMID: 42874103.
- Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Sands BE, Tremaine WJ. ACG Clinical Guideline: Management of Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384-413.
- D'Amico F, Danese S, Peyrin-Biroulet L. Expanding the Therapeutic Armamentarium for Inflammatory Bowel Disease. Lancet Gastroenterol Hepatol. 2023;8(10):945-958.
